PROTAC ER Degrader-3
PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
For research use only. We do not sell to patients.
- CAS No.: 2158322-29-1
- Formula: C71H77N7O12
- Molecular Weight:1220.41
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-13757A
TamoxifenEstrogen Receptor Modulator -
HY-128600
ERD-308ER PROTAC Degrader -
HY-13757AR
Tamoxifen (Standard)Estrogen Receptor Modulator -
HY-128838
PROTAC ERRα Degrader-1PROTAC ERRα Degrader -
HY-112098
PROTAC ERα Degrader-1PROTAC ERα Degrader -
HY-112588
dBET6PROTAC BET Degrader -
HY-111519
dTRIM24PROTAC TRIM24 Degrader -
HY-123921
Gefitinib-based PROTAC 3EGFR PROTAC Degrader -
HY-128839
PROTAC ERRα Degrader-2PROTAC ERRα Degrader -
HY-119932
PROTAC FAK degrader 1PROTAC FAK Degrader -
HY-112495
VH032-PEG5-C6-ClE3 ligase ligand-Linker Conjugate -
HY-114228
PROTAC BET degrader-2BRD2/BRD3/BRD4 PROTAC Degrader
Biological Activity
Description
Chemical Information
-
CAS No. 2158322-29-1
-
Molecular Weight 1220.41
-
Formula C71H77N7O12
-
SMILES
OC1=CC=C(/C(C2=CC=C(OCCN(C)C(COCCOCCNC(C3=CC=C(C(N4[C@@H](C)[C@H](NC([C@H](C)N(C(OC(C)(C)C)=O)C)=O)C(N(CC5=C(OC)C=CC6=C5C=CC=C6)C7=C4C=C(C#N)C=C7)=O)=O)C=C3)=O)=O)C=C2)=C(CC)/C8=CC=CC=C8)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PROTAC ER Degrader-3 Related Classifications
HY-128527 Related Classifications
Powered by Bioz